Advertisement

Therapeutic Control of Atherogenous Primary Hyperlipidemias

  • J. L. de Gennes
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 58)

Abstract

This report reexamines the objectives of medical treatment in primary (or idiopathic) hyperlipidemia. Secondary hyperlipidemias stemming from thyroid, cholestatic, diabetic, and renal etc. origins which require their own specific treatments have therefore been excluded from this discussion.

Keywords

Ursolic Acid Diet Regimen Familial Hypercholesterolemia Atherogenic Risk POrtocaval Shunt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.L. de Gennes, G. Turpin, and J. Truffert, Les pancréatites des hyperlipidémies idiopathiques. Etude d’une série personnelle de 40 cas. Ann. Med. Interne, 125, 4: 333 (1974).Google Scholar
  2. 2.
    J. Davignon, N. Leboeuf, and S. Lussier-Cacan, Aspects nutritionnels du traitement des hyperlipidémies et de l’athérosclérose, Union Médicale, 109, 5: 1 (1980).Google Scholar
  3. 3.
    G. Rosenhamer, and L.A. Carlson, Effect of combined clofibrate-nicotinic acid treatment in ischemic heart disease, Atherosclerosis, 37, 129 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    H. Buchwald, R.B.-Moore, and R.L. Varco, Partial ileal bypass: a test of the lipid-atherosclerosis hypothesis in Atherosclerosis V, A.M. Gotto Jr, L.C. Smith and B. Allen, (eds.), Proceedings of the Fifth International Symposium on Atherosclerosis in Houston, novemver 6–9th 1979, 462.Google Scholar
  5. 5.
    J.L. de Gennes, R. Touraine, G. Maunand, and J. Truffert, Formes homozygotes cutanéo-tendineuses de xanthomatose hypercholestérolémique dans une observation familiale exemplaire. Essai de plasmaphérèse à titre de traitement héro1que, Soc. Med. des Hôp. de Paris, 118, 15: 1377 (1967).Google Scholar
  6. 6.
    J.L. de Gennes, S. Moorjani, M. Lou, D. Brun, and C. Gagne, Removal of cholesterol from blood by affinity binding to heparin-agarose: evaluation of treatment in homozygous familial hypercholesterolemia, Pediat. Res., 14: 113 (1980).CrossRefGoogle Scholar
  7. 7.
    G.R. Thompson, N.B. Myant, D. Kilpatrick C.M. Oakly, M.J. Raphael, and R.E. Steiner, Assessment of long-term plasma exchange for familial hypercholesterolemia, Br. Heart. J., 43:680 (1980)93.Google Scholar
  8. 8.
    T.E. Starlz, H.P. Chose, C.W. Putnam, and K.A. Porter, Portocaval Shunt in hyperlipoproteinemia, Lancet, 2: 940 (1973).Google Scholar
  9. 9.
    T.E. Starlz, L.J. Koep, and R. Weil, Portocaval shunt and Smith, and B. Allen (eds.), Proceeding of the Fifth International Symposium on Atherosclerosis in Houston, November 6–9th 1979, 450.Google Scholar
  10. 10.
    J.L. de Gennes, Les hyperlipidémies idiopathiques. Proposition d’une classification simplifiée, La Nouvelle Presse Médicale, 18: 791 (1971).Google Scholar
  11. 11.
    J.L. de Gennes, F. Dairou, P. Hamon, and J. Truffert, Normalisation lipidique d’un dysbêtalipoprotéinémie de type III par l’éthinyl-oestradiol (50 ug par jour) chez une femme de 87 ans, Ann. Med. Interne, 131, 7: 410 (1980).Google Scholar
  12. 12.
    J.L. de Gennes, F. Dairou, P. Hamon, and J. Truffert, Ultra-centrifugal evidence of a special subtype of mixe hyperlipidemia, Atherosclerosis, 27: 493 (1977).PubMedCrossRefGoogle Scholar
  13. 13.
    J.L. de Gennes,F.Dâiróu, P. Hauron, and J. Truffert, L’hyperlipidémie mixte athérogène à surcharge principale en pré-bêtalipoprotéine lente (tyep IVb), La Nouvelle Presse Médicale, 10, 9: 691 (1981).Google Scholar
  14. 14.
    S.B. Hulley, R.H. Rosenman, R.D. Bawol, and R.J. Brand, Epidemiology as a Guide to Clinical Decisions; the association between triglyceride and coronary heart disease, The New Engl. J. Med., 302, 25: 1383 (1980).CrossRefGoogle Scholar
  15. 15.
    A.R.Tall, and D.M. Small, Plasma high density lipoproteins, The New Engl. J. Med., 299: 1232 (1978).CrossRefGoogle Scholar
  16. 16.
    J.L. Witztum, M.Â. Dillingham, W. Giese, J. Bateman, C. Diekman, E. Kammeyer, S. Weidman, and G. Schonfeld, Normalization of triglycerides in type IV hyperlipoproteinemia fails to correct low levels of high-density-lipoprotein cholesterol, The New Engl. J. Med., 16: 907 (1980).CrossRefGoogle Scholar
  17. 17.
    Coronary Drug Pi ect Rése rch Group: Clofibrate and niacin in coronary heart disease, JAMA, 231: 360 (1980).CrossRefGoogle Scholar
  18. 18.
    W.H.O. Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up, The Lancet, 8191: 397 (1980).Google Scholar
  19. 19.
    J.L. de Gennes, J. Truffert, and P. Periac, Elévation des transaminases glutopyruviques sous traitement par Procétofàne des hyperlipidémies idiopathiques. Fréquence et importance dans 443 cas traités, La Nouvelle Presse Médicale, 7, 27: 2398 (1978).PubMedGoogle Scholar
  20. 20.
    J.L. de Gennes, Intervention trial for secondary CV prevention in primary atherogenous hyperlipidemias, in Atherosclerosis V, G. Schettler, Y. Toto, Y. Hata, and G. Klose (eds.), Proceedings of the Fourth International Symposium on Atherosclerosis in Tokyo, august 24–28th 1976, 686.Google Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • J. L. de Gennes
    • 1
  1. 1.Service d’Endocrinologie MétabolismeHôpital de la PitiéPrais 13èmeFrance

Personalised recommendations